在患有严重过敏性喘且对奥马利祖马布无反应的患者中,杜皮卢马布的有效性
Diego Bagnasco1,2, Benedetta Bondi1,2, Luisa Brussino3
1Respiratory and Allergy Clinic, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Journal of personalized medicine
|February 25, 2025
概括
杜皮卢马布为严重过敏性喘患者提供了有效的替代方案,这些患者对奥马利祖马布无反应,显著减少了恶化和口服皮质类固醇的使用. 它对阿司匹林不耐受或鼻多重症患者特别有益.
科学领域:
- 肺部病理学 肺部病理学
- 过敏学 过敏学
- 临床免疫学临床免疫学
背景情况:
- 严重的过敏喘治疗通常涉及奥马利祖马布.
- 奥马利祖马布并非对所有患者有效.
- 杜比卢马布为不响应者提供了潜在的替代方案.
研究的目的:
- 在严重过敏性喘患者中评估dupilumab的疗效,之前的omalizumab治疗失败.
- 根据口服皮质类固醇 (OCS) 剂量维持,恶化率降低和疾病控制来评估结果.
主要方法:
- 重症喘诊所数据的回顾性分析.
- 在奥马利祖马布失败后转换为杜皮卢马布的观察有效性.
- 包括42名患有严重过敏性喘的患者.
主要成果:
- 杜皮卢马布显著减少了非响应患者的恶化和OCS使用.
- 根据SANI标准,35名患者实现了疾病缓解 (19名完全,16名部分).
- 阿司匹林 (ASA) 不耐受和鼻多重症预测了成功的缓解.
结论:
- 杜皮卢马布有效治疗严重的过敏性喘,特别是在有过敏成分的患者中.
- 患有ASA不耐受或鼻多重症的患者体验到更大的益处.
- 杜皮卢马布代表了耐火病例的有价值的治疗选择.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
226
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
226
Antiasthma Drugs: Leukotriene Modifiers
230
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
230
Drugs Used in Lower Respiratory Disorders: Overview
335
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
335
Antiasthma Drugs: β2-Adrenoceptor Agonists
226
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
226
COPD: Management Using Bronchodilators and Corticosteroids
170
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
170
Dose-Response Relationship: Selectivity and Specificity
6.4K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.4K


